natgillin/translations-raw huggingface dataset:
Since the drug has been marketed, severe allergic reactions (anaphylaxis), hallucinations, and altered mental status have been reported very rarely.
Med trženjem zdravila so o hudih alergijskih reakcijah (anafilaksiji), halucinacijah in spremenjenem duševnem stanju poročali zelo redko.
The first signs of a severe allergic reaction may include swelling of the face and/ or throat.
Prvi znaki hude alergijske reakcije lahko vključujejo otekanje obraza in/ ali grla.
If these symptoms occur you must inform your doctor or nurse immediately.
Če bi tovrstne simptome opazili, o tem takoj obvestite svojega zdravnika ali medicinsko sestro.
HOW TO STORE INVANZ
SHRANJEVANJE ZDRAVILA INVANZ
Do not use INVANZ after the expiry date which is stated on the container.
Zdravila INVANZ ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
What INVANZ contains The active ingredient of INVANZ is ertapenem 1g.
Kaj vsebuje zdravilo INVANZ Zdravilna učinkovina je ertapenem 1 g.
The other ingredients are: sodium bicarbonate (E500) and sodium hydroxide (E524).
Pomožne snovi so: natrijev hidrogenkarbonat (E500) in natrijev hidroksid (E524).
What INVANZ looks like and contents of the pack INVANZ is a sterile, white to off-white, freeze-dried powder.
Izgled zdravila INVANZ in vsebina pakiranja INVANZ je sterilen, bel do sivobel, liofiliziran prašek.
INVANZ 1 g powder for concentrate for solution for infusion is supplied in packs of 1 vial or 10 vials.
INVANZ 1 g prašek za koncentrat za raztopino za infundiranje je na voljo v zloženkah z 1 ali z 10 vialami.
Manufacturer Laboratoires Merck Sharp & Dohme – Chibret Route de Marsat - Riom F-63963 Clermont-Ferrand Cedex 9 France
Laboratoires Merck Sharp & Dohme – Chibret Route de Marsat - Riom F- 63963 Clermont- Ferrand Cedex 9 Francija
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/. --------------------------------------------------------------------------------------------------------------------------------- The following information is intended for medical or healthcare professionals only:
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu /. ---------------------------------------------------------------------------------------------------------------------------------
Adult and adolescents (13 to 17 years of age):
Odrasli in mladostniki (stari od 13 do 17 let):
Reconstitute the contents of a 1 g vial of INVANZ with 10 ml of water for injection or sodium chloride 9 mg/ ml (0.9%) solution to yield a reconstituted solution of approximately 100 mg/ ml.
Vsebino ene viale (1 g zdravila INVANZ) raztopite v 10 ml vode za injekcije ali raztopine natrijevega klorida 9 mg/ ml (0, 9%), da dobite koncentrat s koncentracijo približno 100 mg/ ml.
For a 50 ml bag of diluent:
Za redčenje v 50 ml vreči:
For a 1 g dose, immediately transfer contents of the reconstituted vial to a 50 ml bag of sodium chloride 9 mg/ ml (0.9%) solution; or For a 50 ml vial of diluent:
Za pripravo 1 g odmerka koncentrat iz viale takoj prenesite v 50 ml vrečo raztopine natrijevega klorida 9 mg/ ml (0, 9%); ali Za redčenje v 50 ml viali:
For a 1 g dose, withdraw 10 ml from a 50 ml vial of sodium chloride 9 mg/ ml (0.9%) solution and discard.
Za pripravo 1 g odmerka iz 50 ml viale z raztopino natrijevega klorida 9 mg/ ml (0, 9%) odvzemite 10 ml raztopine in jo zavrzite.
30 Children (3 months to 12 years of age):
Otroci (stari od 3 mesecev do 12 let):
Transfer a volume equal to 15 mg/ kg of body weight (not to exceed 1 g/ day) to a vial of sodium chloride 9 mg/ ml (0.9%) solution for a final concentration of 20 mg/ ml or less.
Za redčenje v infuzijski vreči: v vrečo raztopine natrijevega klorida 9 mg/ ml (0, 9%) prenesite količino, ki ustreza 15 mg/ kg telesne teže (ne sme preseči 1 g/ dan); končna koncentracija naj bo 20 mg/ ml ali manj; ali Za redčenje v viali: v vialo raztopine natrijevega klorida 9 mg/ ml (0, 9%) prenesite količino, ki ustreza 15 mg/ kg telesne teže (ne sme preseči 1 g/ dan); končna koncentracija naj bo 20 mg/ ml ali manj.
Infuse over a period of 30 minutes
Tako pripravljeno raztopino infundirajte 30 minut.
The reconstituted solution should be diluted in sodium chloride 9 mg/ ml (0.9%) solution immediately after preparation.
Koncentrat je treba takoj po pripravi razredčiti v raztopini natrijevega klorida 9 mg/ ml (0, 9%).
Diluted solutions (approximately 20 mg/ ml ertapenem) are physically and chemically stable for 6 hours at room temperature (25°C) or for 24 hours at 2 to 8°C (in a refrigerator).
Razredčena raztopina (približno 20 mg/ ml ertapenema) je fizikalno in kemično stabilna 6 ur pri sobni temperaturi (25 °C) in 24 ur pri temperaturi 2 do 8 °C (v hladilniku).
It is available as prolonged- release tablets (orange-brown:
Na voljo je v obliki tablet s podaljšanim sproščanjem (oranžno- rjavih:
1.5 mg; white:
1, 5 mg; belih:
3 mg; beige:
3 mg; rjavkastih:
6 mg; pink:
6 mg; rožnatih:
9 mg; yellow:
9 mg; rumenih:
12 mg). ‘ Prolonged release ’ means that paliperidone is released slowly from the tablet over a few hours.
„ Podaljšano sproščanje “ pomeni, da se paliperidon iz tablet sprošča počasi več ur.
Invega is used to treat schizophrenia, a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).
Zdravilo Invega se uporablja za zdravljenje shizofrenije, duševne bolezni s številnimi simptomi, kot so nepovezano razmišljanje in govor, halucinacije (prisluhi ali prividi), sumničavost in zmotna prepričanja.
The recommended starting dose of Invega is 6 mg once a day, taken in the morning.
Priporočeni začetni odmerek zdravila Invega je 6 mg enkrat na dan, in sicer zjutraj.
The tablet should be swallowed whole with a drink.
Tableto zdravila Invega je treba pogoltniti celo s tekočino.
Invega should be taken either without food or with breakfast, but patients should not switch between taking the medicine with food on one day and without food on another.
Zdravilo Invega bolniki jemljejo vsako jutro bodisi vedno z zajtrkom ali vedno na tešče, pri čemer je pomembno, da ga vsak dan vzamejo na enak način, t. j. ne sme se jemati enkrat z zajtrkom, naslednji dan pa na tešče.
The dose of Invega can be altered after assessment of symptoms, to a final dose of between 3 and 12 mg once a day.
Odmerek zdravila Invega se lahko prilagodi glede na simptome do končnega odmerka med 3 in 12 mg enkrat dnevno.
It should be used with caution in patients who have severe problems with their liver.
Pri bolnikih s hudimi težavami z jetri se mora uporabljati previdno.
Patients with mild or moderate kidney problems, including some elderly patients, should start with a lower dose of Invega, but it is not recommended for patients with severe kidney problems.
Zdravilo Invega ni priporočljivo za bolnike s hudimi težavami z ledvicami.
Invega has not been studied in patients under 18 years of age.
Zdravilo Invega ni bilo proučeno pri bolnikih, mlajših od 18 let.
It is known as an ‘ atypical’ antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s.
Spada med „ atipične “ antipsihotike, ker se razlikuje od starejših antipsihotikov, ki so v uporabi od petdesetih let prejšnjega stoletja.
Paliperidone is an active breakdown product (metabolite) of risperidone, another antipsychotic medicine that has been used in the treatment of schizophrenia since the 1990s.
Paliperidon je aktivni presnovek risperidona, drugega antipsihotika, ki se za zdravljenje shizofrenije uporablja od devetdesetih let prejšnjega stoletja.
This disrupts signals transmitted between brain cells by ‘ neurotransmitters’, chemicals that allow nerve cells to communicate with each other.
S tem se prekine prenos signalov med možganskimi celicami prek nevrotransmitorjev – kemičnih spojin, ki omogočajo komunikacijo med celicami.
Paliperidone acts mainly by blocking the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin), which are involved in schizophrenia.
Paliperidon večinoma blokira receptorje za nevrotransmitorja dopamin in 5- hidroksitriptamin (imenovanega tudi serotonin), ki sodelujeta pri shizofreniji.
By blocking these receptors, paliperidone helps to normalise the activity of the brain and reduce symptoms.
Z blokiranjem teh receptorjev paliperidon pripomore k normalizaciji dejavnosti možganov in olajša simptome.
The effects of Invega were first tested in experimental models before being studied in humans.
Učinki zdravila Invega so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
Invega has been studied in three main short-term studies involving 1,692 adults with schizophrenia.
Zdravilo Invega so proučili v treh glavnih kratkoročnih študijah, v katere je bilo vključenih 1 692 odraslih s shizofrenijo.
In all three studies, doses of Invega between 3 and 15 mg a day were compared with placebo (a dummy treatment) and with olanzapine (another antipsychotic medicine).
V vseh treh študijah so odmerke zdravila Invega od 3 do 15 mg dnevno primerjali s placebom (zdravilom brez zdravilne učinkovine) in olanzapinom (drugim antipsihotikom).
The main measure of effectiveness was the change in the patients ’ symptoms using a standard scale for schizophrenia after six weeks.
Glavno merilo učinkovitosti je bila sprememba bolnikovih simptomov po standardizirani lestvici za shizofrenijo po šestih tednih zdravljenja.
A further study looked at the long-term effects of Invega in preventing new symptoms for up to 35 weeks in 207 patients who had initially been treated for symptoms of schizophrenia over a 14-week period.
V dodatni študiji so ugotavljali dolgoročne učinke zdravila Invega pri preprečevanju novih simptomov v trajanju do največ 35 tednov pri 207 bolnikih, ki so bili predhodno 14 tednov zdravljeni zaradi simptomov shizofrenije.
Invega was more effective than placebo and as effective as olanzapine in reducing the symptoms of schizophrenia.
Zdravilo Invega je bilo učinkovitejše od placeba in enako učinkovito kot olanzapin pri lajšanju simptomov shizofrenije.
In the first short-term study, patients taking placebo had an average fall in their symptom score of 4.1 points, compared with an average fall of between 17.9 and 23.3 points in those taking Invega and of 19.9 in those taking olanzapine.
V prvi kratkoročni študiji se je pri bolnikih, ki so jemali placebo, rezultat vrednotenja simptomov v povprečju zmanjšal za 4, 1 točke; pri bolnikih, ki so jemali zdravilo Invega, je bilo povprečno zmanjšanje med 17, 9 in 23, 3 točke; pri bolnikih, ki so jemali zdravilo olanzapin, pa 19, 9 točke.
Similar results were seen in the other two short- term studies.
Podobne rezultate so dobili v drugih dveh kratkoročnih študijah.
Across all three studies, higher doses of Invega were more effective than lower doses in reducing symptoms.
V vseh treh študijah so bili pri lajšanju simptomov večji odmerki zdravila Invega učinkovitejši od manjših odmerkov.
Invega was also more effective than placebo in preventing the occurrence of new symptoms of schizophrenia in the long-term study.
Zdravilo Invega je bilo učinkovitejše od placeba tudi v dolgoročni študiji pri preprečevanju pojava novih simptomov shizofrenije.
The most common side effect with Invega (seen in more than 1 patient in 10) is headache.
Najpogostejši neželeni učinek zdravila Invega (opažen pri več kot 1 bolniku od 10) je glavobol.
For the full list of all side effects reported with Invega, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Invega, glejte navodilo za uporabo.
Invega should not be taken by people who may be hypersensitive (allergic) to paliperidone or any of the other ingredients, or to risperidone.
Zdravila Invega ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) paliperidon ali katero koli drugo sestavino zdravila ali risperidon.
The Committee for Medicinal Products for Human Use (CHMP) decided that, at doses of between 3 and 12 mg a day, Invega’ s benefits are greater than its risks for the treatment of schizophrenia.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Invega v odmerkih od 3 do 12 mg dnevno pri zdravljenju shizofrenije večje od z njim povezanih tveganj.
The Committee also concluded that 6 mg once a day was a reasonable starting dose, based on the balance of benefits and risks of the different doses studied.
Glede na razmerje med koristmi in tveganji za različne proučevane odmerke Odbor meni, da je 6 mg enkrat dnevno primeren začetni odmerek.
The Committee recommended that Invega be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Invega odobri dovoljenje za promet.
Other information about Invega:
Druge informacije o zdravilu Invega:
The European Commission granted a marketing authorisation valid throughout the European Union for Invega to Janssen-Cilag International NV on 25 June 2007.
Evropska komisija je dovoljenje za promet z zdravilom Invega, veljavno po vsej Evropski uniji, odobrila družbi Janssen- Cilag International NV dne 25. junija 2007.
The full EPAR for Invega can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Invega je na voljo tukaj.
EU Number EU/ 1/ 07/ 395/ 001 EU/ 1/ 07/ 395/ 002 EU/ 1/ 07/ 395/ 003 EU/ 1/ 07/ 395/ 004 EU/ 1/ 07/ 395/ 005 EU/ 1/ 07/ 395/ 006 EU/ 1/ 07/ 395/ 007 EU/ 1/ 07/ 395/ 008 EU/ 1/ 07/ 395/ 009 EU/ 1/ 07/ 395/ 010 EU/ 1/ 07/ 395/ 011 EU/ 1/ 07/ 395/ 012 EU/ 1/ 07/ 395/ 013 EU/ 1/ 07/ 395/ 014 EU/ 1/ 07/ 395/ 015 EU/ 1/ 07/ 395/ 016 EU/ 1/ 07/ 395/ 017 EU/ 1/ 07/ 395/ 018 EU/ 1/ 07/ 395/ 019 EU/ 1/ 07/ 395/ 020 EU/ 1/ 07/ 395/ 021 EU/ 1/ 07/ 395/ 022 EU/ 1/ 07/ 395/ 023 EU/ 1/ 07/ 395/ 024 EU/ 1/ 07/ 395/ 025 EU/ 1/ 07/ 395/ 026 EU/ 1/ 07/ 395/ 027 EU/ 1/ 07/ 395/ 028 EU/ 1/ 07/ 395/ 029 EU/ 1/ 07/ 395/ 030 EU/ 1/ 07/ 395/ 031 EU/ 1/ 07/ 395/ 032 EU/ 1/ 07/ 395/ 033 EU/ 1/ 07/ 395/ 034 EU/ 1/ 07/ 395/ 035 EU/ 1/ 07/ 395/ 036
Številka EU EU/ 1/ 07/ 395/ 001 EU/ 1/ 07/ 395/ 002 EU/ 1/ 07/ 395/ 003 EU/ 1/ 07/ 395/ 004 EU/ 1/ 07/ 395/ 005 EU/ 1/ 07/ 395/ 006 EU/ 1/ 07/ 395/ 007 EU/ 1/ 07/ 395/ 008 EU/ 1/ 07/ 395/ 009 EU/ 1/ 07/ 395/ 010 EU/ 1/ 07/ 395/ 011 EU/ 1/ 07/ 395/ 012 EU/ 1/ 07/ 395/ 013 EU/ 1/ 07/ 395/ 014 EU/ 1/ 07/ 395/ 015 EU/ 1/ 07/ 395/ 016 EU/ 1/ 07/ 395/ 017 EU/ 1/ 07/ 395/ 018 EU/ 1/ 07/ 395/ 019 EU/ 1/ 07/ 395/ 020 EU/ 1/ 07/ 395/ 021 EU/ 1/ 07/ 395/ 022 EU/ 1/ 07/ 395/ 023 EU/ 1/ 07/ 395/ 024 EU/ 1/ 07/ 395/ 025 EU/ 1/ 07/ 395/ 026 EU/ 1/ 07/ 395/ 027 EU/ 1/ 07/ 395/ 028 EU/ 1/ 07/ 395/ 029 EU/ 1/ 07/ 395/ 030 EU/ 1/ 07/ 395/ 031 EU/ 1/ 07/ 395/ 032 EU/ 1/ 07/ 395/ 033 EU/ 1/ 07/ 395/ 034 EU/ 1/ 07/ 395/ 035 EU/ 1/ 07/ 395/ 036 EU/ 1/ 07/ 395/ 037 EU/ 1/ 07/ 395/ 038 EU/ 1/ 07/ 395/ 039
Invented name Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega
Zaščiteno ime Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega Invega
Strength 3 mg 3 mg 3 mg 3 mg 3 mg 6 mg 6 mg 6 mg 6 mg 6 mg 9 mg 9 mg 9 mg 9 mg 9 mg 12 mg 12 mg 12 mg 12 mg 12 mg 3 mg 3 mg 3 mg 3 mg 3 mg 6 mg 6 mg 6 mg 6 mg 6 mg 9 mg 9 mg 9 mg 9 mg 9 mg 12 mg
Jakost 3 mg 3 mg 3 mg 3 mg 3 mg 6 mg 6 mg 6 mg 6 mg 6 mg 9 mg 9 mg 9 mg 9 mg 9 mg 12 mg 12 mg 12 mg 12 mg 12 mg 3 mg 3 mg 3 mg 3 mg 3 mg 6 mg 6 mg 6 mg 6 mg 6 mg 9 mg 9 mg 9 mg 9 mg 9 mg 12 mg 12 mg 12 mg 12 mg
Pharmaceutical Form Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet Prolonged release tablet
Farmacevtska oblika tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem tableta s podaljšanim sproščanjem
Route of Administration Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use Oral use
Pot uporabe peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba
Packaging blister (PVC/ PCTFE/ alu) asdf blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu) blister (white PVC/ PCTFE/ alu)
Ovojnina pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu) pretisni omot (bel PVC/ PCTFE/ alu)
Package size 28 tablets 30 tablets 49 tablets 56 tablets 98 tablets 28 tablets 30 tablets 49 tablets 56 tablets 98 tablets 28 tablets 30 tablets 49 tablets 56 tablets 98 tablets 28 tablets 30 tablets 49 tablets 56 tablets 98 tablets 28 tablets 30 tablets 49 tablets 56 tablets 98 tablets 28 tablets 30 tablets 49 tablets 56 tablets 98 tablets 28 tablets 30 tablets 49 tablets 56 tablets 98 tablets 28 tablets
Velikost pakiranja 28 tablet 30 tablet 49 tablet 56 tablet 98 tablet 28 tablet 30 tablet 49 tablet 56 tablet 98 tablet 28 tablet 30 tablet 49 tablet 56 tablet 98 tablet 28 tablet 30 tablet 49 tablet 56 tablet 98 tablet 28 tablet 30 tablet 49 tablet 56 tablet 98 tablet 28 tablet 30 tablet 49 tablet 56 tablet 98 tablet 28 tablet 30 tablet 49 tablet 56 tablet 98 tablet 28 tablet 30 tablet 49 tablet 56 tablet
EU/ 1/ 07/ 395/ 037 EU/ 1/ 07/ 395/ 038 EU/ 1/ 07/ 395/ 039 EU/ 1/ 07/ 395/ 040 EU/ 1/ 07/ 395/ 041 EU/ 1/ 07/ 395/ 042 EU/ 1/ 07/ 395/ 043 EU/ 1/ 07/ 395/ 044 EU/ 1/ 07/ 395/ 045 EU/ 1/ 07/ 395/ 046 EU/ 1/ 07/ 395/ 047 EU/ 1/ 07/ 395/ 048 EU/ 1/ 07/ 395/ 049 EU/ 1/ 07/ 395/ 050 EU/ 1/ 07/ 395/ 051 EU/ 1/ 07/ 395/ 052 EU/ 1/ 07/ 395/ 053 EU/ 1/ 07/ 395/ 054 EU/ 1/ 07/ 395/ 055 EU/ 1/ 07/ 395/ 056 EU/ 1/ 07/ 395/ 057 EU/ 1/ 07/ 395/ 058 EU/ 1/ 07/ 395/ 059 EU/ 1/ 07/ 395/ 060 EU/ 1/ 07/ 395/ 061 EU/ 1/ 07/ 395/ 062 EU/ 1/ 07/ 395/ 063 EU/ 1/ 07/ 395/ 064 EU/ 1/ 07/ 395/ 065 EU/ 1/ 07/ 395/ 066 EU/ 1/ 07/ 395/ 067 EU/ 1/ 07/ 395/ 068 EU/ 1/ 07/ 395/ 069 EU/ 1/ 07/ 395/ 070 EU/ 1/ 07/ 395/ 071 EU/ 1/ 07/ 395/ 072 EU/ 1/ 07/ 395/ 073
EU/ 1/ 07/ 395/ 040 EU/ 1/ 07/ 395/ 041 EU/ 1/ 07/ 395/ 042 EU/ 1/ 07/ 395/ 043 EU/ 1/ 07/ 395/ 044 EU/ 1/ 07/ 395/ 045 EU/ 1/ 07/ 395/ 046 EU/ 1/ 07/ 395/ 047 EU/ 1/ 07/ 395/ 048 EU/ 1/ 07/ 395/ 049 EU/ 1/ 07/ 395/ 050 EU/ 1/ 07/ 395/ 051 EU/ 1/ 07/ 395/ 052 EU/ 1/ 07/ 395/ 053 EU/ 1/ 07/ 395/ 054 EU/ 1/ 07/ 395/ 055 EU/ 1/ 07/ 395/ 056 EU/ 1/ 07/ 395/ 057 EU/ 1/ 07/ 395/ 058 EU/ 1/ 07/ 395/ 059 EU/ 1/ 07/ 395/ 060 EU/ 1/ 07/ 395/ 061 EU/ 1/ 07/ 395/ 062 EU/ 1/ 07/ 395/ 063 EU/ 1/ 07/ 395/ 064 EU/ 1/ 07/ 395/ 065 EU/ 1/ 07/ 395/ 066 EU/ 1/ 07/ 395/ 067 EU/ 1/ 07/ 395/ 068 EU/ 1/ 07/ 395/ 069 EU/ 1/ 07/ 395/ 070 EU/ 1/ 07/ 395/ 071 EU/ 1/ 07/ 395/ 072 EU/ 1/ 07/ 395/ 073 EU/ 1/ 07/ 395/ 074 EU/ 1/ 07/ 395/ 075 EU/ 1/ 07/ 395/ 076 EU/ 1/ 07/ 395/ 077 EU/ 1/ 07/ 395/ 078 EU/ 1/ 07/ 395/ 079 EU/ 1/ 07/ 395/ 080 EU/ 1/ 07/ 395/ 081 EU/ 1/ 07/ 395/ 082 EU/ 1/ 07/ 395/ 083 EU/ 1/ 07/ 395/ 084 EU/ 1/ 07/ 395/ 085 EU/ 1/ 07/ 395/ 086 EU/ 1/ 07/ 395/ 087 EU/ 1/ 07/ 395/ 088 EU/ 1/ 07/ 395/ 089 EU/ 1/ 07/ 395/ 090 EU/ 1/ 07/ 395/ 091 EU/ 1/ 07/ 395/ 092 EU/ 1/ 07/ 395/ 093 EU/ 1/ 07/ 395/ 094 EU/ 1/ 07/ 395/ 095